EBS News and Press, Emergent Biosolutions Inc. From 11/05/21

Earnings news remained the crucial driver during Friday's midday action. Airbnb (NASDAQ:ABNB), Pinterest (NYSE:PINS) and Uber (NYSE:UBER) all showed notable gains following the release of their quarterly reports. Elsewhere, Emergent (NYSE:EBS) lost about two-fifths of its value after disclosi...

Shares of Emergent Biosolutions (NYSE: EBS) have crashed 41.1% as of 11:44 a.m. EDT on Friday. The huge decline came after the company revealed on Thursday that a multimillion-dollar agreement with the U.S. Department of Health and Human Services (HHS) had been canceled. Emergen...

Image source: The Motley Fool. Emergent BioSolutions inc (NYSE: EBS) Q3 2021 Earnings Call Nov 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions inc (EBS) Q3 2021 Earnings Call Transcript

Emergent BioSolutions (NYSE:EBS) shares fell 15% in after-hours trading after the company revealed during its Q3 2021 earnings call that the federal government has terminated a contract as part of a pandemic preparedness plan. The Center for Innovation in Advanced Development and Ma...

Emergent BioSolutions Inc. (EBS) Q3 2021 Earnings Conference Call November 04, 2021 05:00 PM ET Company Participants Bob Burrows - Investor Relations Officer Bob Kramer - President & Chief Executive Officer Rich Lindahl - Chief Financial Officer Conference Call Participants Brandon Folkes...

Emergent Biosolutions (NYSE:EBS): Q3 Non-GAAP EPS of -$0.36 misses by $2.64; GAAP EPS of $0.61 misses by $1.33. Revenue of $329M (-14.6% Y/Y) misses by $155.77M. Press Release Outlook: Total revenues: Updated 2021 Forecast $1.7B - $1.8B; Previous 2021 Forecast $1.7B - $1.9...

GAITHERSBURG, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2021. "Emergent's core products and service businesses remain strong as evidenced by our accomplishments this qua...

NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advan...

GAITHERSBURG, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial results for the third quarter of 2021, recent business developments, and financial outlook f...

GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus (CHIKV) virus-like particle ...